Department of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, Colorado, USA.
Flint Animal Cancer Center, Colorado State University, Fort Collins, Colorado, USA.
J Vet Intern Med. 2023 Nov-Dec;37(6):2356-2367. doi: 10.1111/jvim.16838. Epub 2023 Sep 8.
Stereotactic radiotherapy (SRT) is an emerging treatment for sinonasal tumors in dogs. Reported results regarding tumor control and incidence of acute and late radiation morbidities are inconsistent.
To determine treatment efficacy and prognostic indicators of SRT in dogs with sinonasal tumors and to quantify acute and late radiation morbidities.
One hundred and eighty-two client-owned dogs with sinonasal tumors diagnosed cytologically, histologically, or radiographically that underwent SRT.
Single-arm retrospective study by reviewing medical records of dogs treated with SRT (10 Gy × 3) between 2010 and 2015. Kaplan-Meier analysis was used to determine overall survival (OST; from the first day of SRT to death by any cause) and disease-specific survival times (DSST; OST but censoring tumor/treatment-unrelated death). Tumors were staged using modified Adams criteria.
Median OST and DSST of dogs treated with 1 course of SRT was 441 (95% CI: 389-493 days) and 482 (428-536 days) days, respectively with skin/oral cavity acute morbidities observed in 3% of dogs. DSST in dogs with stage 4 disease showed no statistical difference compared to other stages (P = .64). Oro-nasal (n = 2) or naso-cutaneous (n = 11) fistula development occurred in 7.1% of dogs with median time of 425 days (range: 83-1733 days). Possible chronic rhinitis after SRT was recorded in 54 of 88 dogs (61%) where information was available.
Results are comparable to other reports of treatment of SRT. Acute morbidities were minimal. Modified Adams stage scheme appeared to be inappropriate for prognostication for dogs with sinonasal tumors treated with SRT.
立体定向放射治疗(SRT)是一种治疗犬鼻窦肿瘤的新兴方法。关于肿瘤控制和急性及迟发性放射并发症发生率的报道结果不一致。
确定 SRT 治疗犬鼻窦肿瘤的疗效和预后指标,并量化急性和迟发性放射并发症。
182 只经细胞学、组织学或影像学诊断患有鼻窦肿瘤并接受 SRT 治疗的患犬。
回顾性单臂研究,对 2010 年至 2015 年间接受 SRT(10Gy×3)治疗的犬的病历进行了回顾。采用 Kaplan-Meier 分析确定总生存时间(OST;从 SRT 治疗的第一天到任何原因导致的死亡)和疾病特异性生存时间(DSST;OST,但对肿瘤/治疗无关的死亡进行删失)。使用改良的 Adams 标准对肿瘤进行分期。
接受 1 疗程 SRT 治疗的犬的中位 OST 和 DSST 分别为 441(95%CI:389-493 天)和 482(428-536 天)天,3%的犬出现皮肤/口腔腔急性并发症。IV 期疾病犬的 DSST 与其他分期无统计学差异(P=0.64)。7.1%(n=2)的犬出现口-鼻(n=11)瘘,中位时间为 425 天(范围:83-1733 天)。在有信息可查的 88 只犬中,54 只(61%)犬在 SRT 后出现可能的慢性鼻炎。
结果与 SRT 治疗的其他报道相似。急性并发症很少见。改良的 Adams 分期方案似乎不适合预测接受 SRT 治疗的鼻窦肿瘤犬的预后。